<DOC>
	<DOCNO>NCT02157870</DOCNO>
	<brief_summary>Multi-Phase study ( I/II ) progress Phase II clinical trial , terminate early due low accrual , separate ClinicalTrials.gov Registration NCT00102622 Phase I study : Phase I : - Enrollment 24 subject 8 cohort three subject one three combination intraperitoneal ( IP ) tgDCC-E1A + intravenous ( IV ) paclitaxel continuous reassessment method ( CRM ) sufficient establish MTD - The single agent paclitaxel cohort consist 24 subject Phase II : - Enrollment 20 subject one three combination IP tgDCC-E1A + IV paclitaxel decide Phase I . - The single-agent paclitaxel cohort consist 20 subject .</brief_summary>
	<brief_title>A Randomized Study Intraperitoneal tgDCC-E1 Intravenous Paclitaxel Women With Platinum-Resistant Ovarian Cancer</brief_title>
	<detailed_description>Primary Objective - To evaluate toxicity establish maximum tolerate dose ( MTD ) intraperitoneal tgDCC-E1A combination intravenous paclitaxel . ( Phase I ) - To measure tumor response intraperitoneal tgDCC-E1A combination intravenous paclitaxel compare intravenous paclitaxel . ( Phase II ) Secondary Objective - To measure time progression overall survival . - To examine biological effect combine tgDCC- E1A paclitaxel ovarian cancer cell measure laboratory testing . Epithelial ovarian cancer significant public health problem . It sixth common cancer woman worldwide . Globally , estimate 162,000 new case diagnose per year , 106,000 woman die disease per year . Signs symptoms ovarian cancer often subtle . Seventy-five percent subject present advanced stage III IV disease . Standard treatment stage III/IV subject consist surgical debulking maximal extent possible chemotherapy paclitaxel plus platinum compound ( cisplatin carboplatin ) . Despite high initial response rate , overall survival group poor , 20 % stage III le 5 % stage IV subject survive five year . Treatment recurrent ovarian cancer varies depend upon interval prior treatment recurrence . Twenty percent subject classify `` platinum-refractory '' , fail even partial response platinum-containing regimen . Subjects recurrent progressive disease less six month initial therapy poor response rate repeat treatment platinum-containing regimen , generally consider `` platinum-resistant '' disease . In contrast , subject recurrent disease great six month initial therapy well response rate repeat treatment platinum-containing regimen , generally consider `` platinum-sensitive '' disease . There consensus treatment `` platinum-refractory '' `` platinum-resistant '' ovarian cancer , class individual particularly challenge treat . Prognosis poor , treatment primarily palliative nature . Responses variety single chemotherapeutic agent , well combination agent largely phase II trial similar , range 10-35 % . Intravenous ( IV ) paclitaxel , give alone combination agent standard treatment subject relapse . In attempt increase dose intensity paclitaxel therapy , weekly IV paclitaxel recommend . This treatment schedule well tolerate , response rate heavily pretreated subject still 28.9 % . Given group subject poorly responsive conventional chemotherapy , consequently limit option , alternative approach treatment warrant . The use gene therapy agent anti-tumor effect ability sensitize cancer cell traditional chemotherapy appeal . - Overview Effect E1A Gene Transfer Cancer Cells : E1A , gene derive Adenovirus type 5 , show potent anti-neoplastic activity variety mechanism , include down-regulation HER-2/neu overexpression , induction apoptosis , inhibition metastasis , reversion tumor cell toward differentiate epithelial phenotype . The E1A gene also show additive effect vitro vivo apoptosis induce chemotherapy radiotherapy . The E1A gene successfully transfected human cell vitro vivo use tgDCC-E1A ( E1A-Lipid Complex ) , consist E1A plasmid ( pE1A-K2 ) complexed cationic lipid gene delivery system comprise DC-Cholesterol 3b [ N- ( N ' N'-dimethylaminoethane ) -carbamoyl ] cholesterol hydrochloride DOPE ( 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine ) . - Rationale Use Cationic Lipids Deliver DNA : Cationic lipid form complex negatively charge DNA plasmid facilitate transfer gene target cell . They useful agent delivery gene therapy synthesize chemically , simple manufacture , pose infectious risk . The cationic derivative cholesterol , 3b [ N- ( N ' N'-dimethylaminoethane ) -carbamoyl ] cholesterol hydrochloride ( DC-Chol ) ideal cationic lipid therapeutic use , cationic charge provide non-toxic tertiary amine biodegradable carbamoyl bond . DC-Chol use prepare liposomes combination neutral 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine ( DOPE ) DC-Chol DOPE ratio 6:4 . This liposome combination mixed plasmid encode E1A form tgDCC-E1A . The final preparation tgDCC-E1A make within range lipid : DNA ratio , show cell culture animal model result expression E1A . Clinical trial tgDCC-E1A injection solid tumor use final preparation lipid : DNA ratio 1 nmol lipid 1 microgram DNA [ tgDCC-E1A ( 1:1 ) ] . Early clinical trial evaluate intracavitary administration ( e.g . intraperitoneal infusion ovarian cancer ) use preparation lipid : DNA ratio 10 nmol lipid 1 microgram DNA [ tgDCC-E1A ( 10:1 ) ] . More recent protocol intraperitoneal delivery ovarian cancer use preparation lipid : DNA ratio 3 nmol lipid 1 microgram DNA [ tgDCC-E1A ( 3:1 ) ] , protocol . - Rationale Intraperitoneal Delivery tgDCC-E1A : The peritoneal cavity common site tumor recurrence initial `` radical '' surgical treatment ovarian malignancy . Dissemination cavity often widespread . Because unusual natural course ovarian cancer ( characterized tendency confine peritoneal cavity ) , control metastatic disease peritoneal cavity important challenging problem , improve direct delivery drug peritoneal cavity .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Age great equal 18 year Recurrent epithelial ovarian cancer primary peritoneal cancer histologic confirmation original tumor . Recurrent disease may manifest elevated cancer antigen ( CA ) 125 use follow criterion : ( ) increase CA125 least 2 time upper limit normal ( assayed 2 occasion least 7 day apart ) subject history normal pretreatment value value normalized recent treatment OR ( b ) increase CA125 2 time lowest observe value recent treatment ( assayed two occasion least 7 day apart ) subject whose CA125 normalize recent treatment . Platinumresistant disease , define recurrence less six month discontinuation treatment platinum therapy platinumrefractory disease define progression platinumcontaining regimen . A treatmentfree interval least three week cytotoxic therapy , radiation therapy , experimental drug prior first treatment protocol . A Zubrod performance status two less . Previous administration tgDCCE1A . Progression taxanecontaining regimen , recurrent within 6 month receive weekly taxanecontaining regimen . Previous radiation 25 % marrowbearing area . Any following laboratory value : Hemoglobin &lt; 9.0 gm/dl , absolute neutrophil count ( ANC ) &lt; 1.5 K/ml , platelet &lt; 100 K/ml , creatinine &gt; 2 mg/dl , bilirubin &gt; 2 mg/dl , Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) &gt; 2 time upper limit normal , abnormal coagulation profile ( &gt; 2 second beyond upper range normal Prothrombin Time ( PT ) Partial thromboplastin time ( PTT ) ) . Known human immunodeficiency virus ( HIV ) positive status active systemic infection . History invasive malignancy , except nonmelanoma skin cancer , unless evidence cancer within past 5 year . Patients grade 2 great neurotoxicity . Patients unstable angina myocardial infarction within past six month . Patients evidence abnormal cardiac conduction eligible disease stable past six month . Patients ejection fraction 40 % .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Ovary</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>biologic therapy</keyword>
	<keyword>platinum-resistant</keyword>
	<keyword>platinum-refractory ovarian cancer</keyword>
	<keyword>platinum-resistant ovarian cancer</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>tgDCC-E1A</keyword>
	<keyword>E1A</keyword>
	<keyword>Taxol</keyword>
</DOC>